文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

化合物和纳米颗粒向肿瘤的组织穿透递送。

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

作者信息

Sugahara Kazuki N, Teesalu Tambet, Karmali Priya Prakash, Kotamraju Venkata Ramana, Agemy Lilach, Girard Olivier M, Hanahan Douglas, Mattrey Robert F, Ruoslahti Erkki

机构信息

Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, Biology II Building, University of California, Santa Barbara, Santa Barbara, CA 93106-9610, USA.

出版信息

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.


DOI:10.1016/j.ccr.2009.10.013
PMID:19962669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2791543/
Abstract

Poor penetration of drugs into tumors is a major obstacle in tumor treatment. We describe a strategy for peptide-mediated delivery of compounds deep into the tumor parenchyma that uses a tumor-homing peptide, iRGD (CRGDK/RGPD/EC). Intravenously injected compounds coupled to iRGD bound to tumor vessels and spread into the extravascular tumor parenchyma, whereas conventional RGD peptides only delivered the cargo to the blood vessels. iRGD homes to tumors through a three-step process: the RGD motif mediates binding to alphav integrins on tumor endothelium and a proteolytic cleavage then exposes a binding motif for neuropilin-1, which mediates penetration into tissue and cells. Conjugation to iRGD significantly improved the sensitivity of tumor-imaging agents and enhanced the activity of an antitumor drug.

摘要

药物在肿瘤中的低渗透性是肿瘤治疗的主要障碍。我们描述了一种通过肽介导将化合物深入递送至肿瘤实质的策略,该策略使用肿瘤归巢肽iRGD(CRGDK/RGPD/EC)。静脉注射与iRGD偶联的化合物会与肿瘤血管结合并扩散到血管外肿瘤实质中,而传统的RGD肽仅将货物递送至血管。iRGD通过三步过程归巢至肿瘤:RGD基序介导与肿瘤内皮细胞上的αv整合素结合,然后蛋白水解切割暴露神经纤毛蛋白-1的结合基序,该基序介导穿透组织和细胞。与iRGD偶联显著提高了肿瘤成像剂的敏感性,并增强了抗肿瘤药物的活性。

相似文献

[1]
Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Cancer Cell. 2009-12-8

[2]
Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.

J Control Release. 2016-9-10

[3]
Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?

J Drug Target. 2015-12

[4]
iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.

J Oncol. 2019-6-26

[5]
Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Biomaterials. 2014-7-11

[6]
iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Biomaterials. 2016-10

[7]
Tumor-penetrating peptides.

Front Oncol. 2013-8-27

[8]
De novo design of a tumor-penetrating peptide.

Cancer Res. 2012-11-14

[9]
Tumor-penetrating iRGD peptide inhibits metastasis.

Mol Cancer Ther. 2015-1

[10]
Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.

Int J Nanomedicine. 2019-11-1

引用本文的文献

[1]
A cytotoxic peptide-drug conjugate for tumor-specific delivery of co-injected molecules.

PLoS One. 2025-9-2

[2]
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways.

Pharmaceuticals (Basel). 2025-7-26

[3]
Dynamic Susceptibility Contrast Magnetic Resonance Imaging with Carbon-Encapsulated Iron Nanoparticles Navigated to Integrin Alfa V Beta 3 Receptors in Rat Glioma.

Nanomaterials (Basel). 2025-8-18

[4]
Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide.

Sci Rep. 2025-8-11

[5]
CeO nanozyme-embedded thermal-deformative polymer for site-specific chemotherapy via HIF-1α-P-gp/lipolysis axis reversal.

Asian J Pharm Sci. 2025-6

[6]
Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade.

Cancer Immunol Immunother. 2025-5-30

[7]
Targeted Dual-Responsive Liposomes Co-Deliver Jolkinolide B and Ce6 to Synergistically Enhance the Photodynamic/Immunotherapy Efficacy in Gastric Cancer through the PANoptosis Pathway.

Adv Sci (Weinh). 2025-8

[8]
Enhanced delivery of camptothecin to colorectal carcinoma using a tumor-penetrating peptide targeting p32.

Acta Biomater. 2025-6-15

[9]
Peptide-based drugs in immunotherapy: current advances and future prospects.

Med Oncol. 2025-4-23

[10]
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications.

Int J Mol Sci. 2025-3-28

本文引用的文献

[1]
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Proc Natl Acad Sci U S A. 2009-9-22

[2]
HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Blood. 2009-5-21

[3]
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.

Small. 2009-3

[4]
Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Nanomedicine. 2009-3

[5]
Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma.

Cancer Res. 2008-9-1

[6]
Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells.

Cancer Res. 2008-9-1

[7]
In vivo tumor cell targeting with "click" nanoparticles.

Bioconjug Chem. 2008-8

[8]
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Proc Natl Acad Sci U S A. 2008-7-8

[9]
Neuropilins: structure, function and role in disease.

Biochem J. 2008-4-15

[10]
Nanoparticles for drug delivery in cancer treatment.

Urol Oncol. 2008

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索